O304 rapidly reduced glucose levels without enhancing plasma insulin levels also in STZ mice where the treatment was initiated first at day 15, i.e., when the mice had developed overt diabetes (Fig. 1g and Supplementary Fig. 1e) (Fig. 1h). The gene discussed is INS; the disease is diabetes mellitus.